CRT-400.26 Transfemoral Aortic Valve Implantation in Patients with Symptomatic Severe Aortic Stenosis with the Repositionable Lotus Valve: Results from a High Volume Center

Jochen Wöhrle,Birgid Gonska,Christoph Rodewald,Julia Seeger,Dominik Scharnbeck,Wolfgang Rottbauer

JACC cardiovascular interventions/JACC Cardiovascular interventions（2016）

引用 0|浏览10

暂无评分

摘要

The Lotus valve (Boston Scientific Corporation) is designed to reduce the risk for residual paravalvular aortic regurgitation and can be easily repositioned. The study evaluates the procedural and 30-day results for the 23, 25 and 27mm Lotus valve in patients undergoing transfemoral aortic valve

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要